The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Utilization of adjuvant trastuzumab for T1a,b N0 HER2+ breast cancer in Ontario.
Andrea Eisen
Research Funding - Roche Canada
Lyndee Yeung
No relevant relationships to disclose
Scott Gavura
No relevant relationships to disclose
Zachary M Brown
No relevant relationships to disclose
Maureen E. Trudeau
Research Funding - Roche Canada